Journal of Pediatrics & Child Care
Case Report
Neonatal Macrocytic Anemia Following in Utero Exposure to Triumeq (Abacavir/Dolutegravir/Lamivudine): A Case Report
Pan M1 and Jain SK2*
1John Sealy School of Medicine, University of Texas Medical Branch, Galveston, TX, USA
2Department of Pediatrics, University of Texas Medical Branch, Galveston, TX, USA
2Department of Pediatrics, University of Texas Medical Branch, Galveston, TX, USA
*Address for Correspondence:Sunil K. Jain, Department of Pediatrics, University of Texas
Medical Branch, Galveston, TX, USA E-mail Id: skjain@utmb.edu
Submission: 19 December, 2024
Accepted: 26 February, 2025
Published: 04 March, 2025
Copyright: © 2025 Pan M, et al. This is an open access article
distributed under the Creative Commons Attr-ibution License,
which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited.
Abstract
We report a case of neonatal macrocytic anemia in dizygotic
twins born to an HIV-positive mother treated with Triumeq during
pregnancy. Despite achieving an undetectable maternal viral load,
both twins required NICU care for metabolic acidosis and respiratory
distress and developed severe anemia necessitating transfusions.
This is the first documented case of fetal and neonatal macrocytic
anemia associated with Triumeq, highlighting the need for awareness
of potential hematologic side effects of antiretroviral therapy (ART) in
pregnancy.